Illimis Therapeutics

Developer of antibody-based drugs to treat neurological conditions

placeSeoul, Seoul, South Korea calendar_todayFounded 2021 groups26 employees language illimistx.com

Innovation

4 patent families (1 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace accelerating. Cited 169 times.

YearFilings
20221
20231
20242
20254
20262

Social engagement

Social engagement: 592 social following, 4 posts in the last 12 months — below the industry typical range.

Investor mix

22 investors on record; lead investors include Aju IB Investment.

Investor typeCountShare
Venture capital1359%
Private equity418%
Bank & private debt15%
Other / undisclosed418%

Recent activity

3 Feb 2026
Event
AD/PDTM 2026
28 Jul 2025
Event
AAIC2025
Coming soon